WithdrawnPhase 2/3

Propranolol Administration in Pediatric Patients With Recurrent Respiratory Papillomatosis

Stopped: No participants enrolled

0Started 2010-01

Plain-language summary

Juvenile onset recurrent respiratory papillomatosis (JORRP) is a rare, difficult to treat, benign tumor of the pediatric airway. Current therapy is mainly surgical, but in a significant portion of patients adjuvant therapy is required to control the disease process. Although multiple adjuvant medical therapies have been tried, success has been limited. We have seen some success in a limited amount of patients using orally administered propranolol. Our goal is to enroll a larger cohort of patients to determine the effectiveness of propranolol as an adjuvant therapy for JORRP.

Who can participate

Age range1 Year – 10 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * 1\. Biopsy proven with appropriate Human Papilloma Virus typing Recurrent Respiratory Papilloma * 2\. Child under age 10 * 3\. Informed consent and where appropriate informed assent * 4\. Children who have undergone at least 4 documented surgical interventions in the past year. Exclusion Criteria: * Parental or child refusal to participate * Heart failure * Atrio-ventricular heart block * Cardiac anomalies * Low resting heart rate * Low resting blood pressure * Wolff-Parkinson White Syndrome * Unexplained syncope * Asthma or Reactive airway disease * Renal or liver failure * Expected long fasting periods, \>12 hours * Diabetes Mellitus * Hypersensitivity to propranolol

What they're measuring

Decreased number of surgeries

Timeframe: 3 months

Trial details

NCT IDNCT01058317

SponsorMassachusetts Eye and Ear Infirmary

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2010-09

View on ClinicalTrials.gov More Recurrent Respiratory Papillomatosis trials